Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA

NCT00688428 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00688428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00688428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
April 30, 2008
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcers, upper gi symptoms